Tham khảo Milrinone

  1. ↑ Packer, M. Calcium channel blockers in chronic heart failure: The risks of ‘ physiologically rational ’ therapy [Editorial]. Circulation 8 2,2254 – 2257.
  2. ↑ Packer M, Carver J, Rodeheffer R, Ivanhoe R, DiBianco R, Zeldis S et al. Effect of Oral Milrinone on Mortality in Severe Chronic Heart Failure. The New England Journal of Medicine. 21 Nov 1991;325(21):1468-1475.
  3. ↑ Fleming G, Murray K, Yu C, Byrne J, Greelish J, Petracek M et al. Milrinone Use Is Associated With Postoperative Atrial Fibrillation After Cardiac Surgery. The Journal of the American Heart Association. 29 Sept 2008;118:1619-1625.
  4. ↑ British National Formulary. 66 ed. London: BMJ Group and Pharmaceutical Press; Sept 2013
  5. ↑ Koster, Geert; Bekema, Hanneke J.; Wetterslev, Jørn; Gluud, Christian; Keus, Frederik; van der Horst, Iwan C. C. (22 tháng 7 năm 2016). “Milrinone for cardiac dysfunction in critically ill adult patients: a systematic review of randomised clinical trials with meta-analysis and trial sequential analysis”. Intensive Care Medicine. 42 (9): 1322–1335. doi:10.1007/s00134-016-4449-6. PMC 4992029. PMID 27448246.
  6. ↑ McNamara, Patrick J.; Shivananda, Sandesh P.; Sahni, Mohit; Freeman, David; Taddio, Anna (tháng 1 năm 2013). “Pharmacology of Milrinone in Neonates With Persistent Pulmonary Hypertension of the Newborn and Suboptimal Response to Inhaled Nitric Oxide*”. Pediatric Critical Care Medicine. 14 (1): 74–84. doi:10.1097/PCC.0b013e31824ea2cd. ISSN 1529-7535. PMID 23132395.
  7. ↑ Hui-li, Gan (tháng 6 năm 2011). “The Management of Acute Pulmonary Arterial Hypertension: The Management of Acute Pulmonary Hypertension”. Cardiovascular Therapeutics. 29 (3): 153–175. doi:10.1111/j.1755-5922.2009.00095.x. PMID 20560976.